BioSpace News Archive

CURE Media Group, which reaches over 1 million patients, survivors and caregivers across an industry-leading multimedia platform devoted solely to cancer updates and research, announces the addition of the Hairy Cell Leukemia Foundation to its Strategic Alliance Partnership (SAP) program.

InMed’s Eric Hsu and Michael Woudenberg among Event’s Expert Speakers

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that it is planning a proof of concept (POC) clinical trial for the use of its RAP technology for the treatment of keloid and hypertrophic scars.

Can-Fite BioPharma Ltd. announced financial results for the six months ended June 30, 2019.

MEI Pharma, Inc. (NASDAQ: MEIP), a late‐stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief executive officer, will present at the 2019 Wells Fargo Global Healthcare Conference

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that members of its management team will participate in the following upcoming conferences in September:

Ocular Therapeutix, Inc. (NASDAQ:OCUL) today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will give a company presentation on Thursday, September 5th at 2:30 p.m. EDT at the 2019 Wells Fargo Healthcare Conference at the Westin Copley Place Hotel in Boston, MA.

Medicine Man Technologies, Inc. (OTCQX: MDCL) (“Medicine Man Technologies” or the “Company”) today announced the appointment of Nancy Bush Huber as the Company’s Vice President (VP) of Finance.

CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming investor conferences.

VenatoRx Pharmaceuticals today announced that it has initiated enrollment in its Phase 3 trial of cefepime/VNRX-5133 in patients with complicated urinary tract infections (cUTIs).